[ Editorials | Departments and Series | Index ]


Contraception Corner

Just Say No Every Now and Then

Anita L. Nelson, MD; Miriam Zieman, MD

Today, we have remarkably convenient, reversible methods of contraception that are as effective as sterilization. We have hormonal methods of birth control that offer a wide range of important health benefits, as well as provide contraceptive protection. Despite these developments, there are many couples who, for personal, cultural, and/or religious reasons, choose not to avail themselves of these methods or of any of the barrier options. Instead, they prefer to rely on techniques that are curiously referred to as “natural family planning” (NFP) methods. More correctly, these techniques are called “periodic abstinence” or the “fertility awareness method” (FAM). In periodic abstinence, the couple avoids intercourse during the at-risk days. In FAM, they use another method (such as condoms or withdrawal) during the at-risk days. To implement either form of “natural” family planning, it is necessary to calculate when a woman is about to ovulate or has recently ovulated and is vulnerable to pregnancy. Is “natural family planning” truly “natural”? Instead, it is more accurate to characterize these methods as “behavioral methods” along with withdrawal and lactational amenorrhea.

As health care providers, we have a responsibility to those couples who select these approaches to ensure that the methods are as effective as possible in protecting against pregnancy. While there are no medical contraindications to use of these methods, they are not indicated for women with irregular menses, such as women with polycystic ovarian syndrome, breast-feeding, or perimenopausal hormonal fluctuations. Several techniques are used to detect the at-risk days, but the typical failure rate for periodic abstinence is 25%.1

The calendar or “rhythm” method is based upon analysis of recordings of actual menstrual cycling. Because women frequently do not record exact dates of their menses, this information must generally be accumulated prospectively over 6 to 9 months, depending on the consistency of the woman’s cycle length. From these data, the extremes of cycle length are identified, and the days of abstinence are calculated with the assumption that the sperm survive 5 days, the ovum survives for 1 day, and the luteal phase is 12 to 16 days long. Using these assumptions, the at-risk days can be calculated using these simple rules:

  • The first day of abstinence = the number of days of the shortest cycle minus 18.
  • The last day of abstinence = the number of days of the longest cycle minus 11.

Using these formulas, it can be seen that the greater the variability in a woman’s cycle length, the greater the number of days of abstinence. A woman with a perfectly consistent cycle length of 28 days would have to abstain during cycle days 10 to 17, or 8 days per cycle. A woman whose cycle lengths varied between 26 and 30 days would have to abstain during cycle days 8 to 19, or 12 days per cycle.

The Billings method or ovulation method relies on the changes that ovarian hormone production has on cervical mucus. After menses, the cervical mucus is scant and dry. It thickens and increases in amount and stickiness until near ovulation, when it becomes abundant, slippery, clear, and elastic under the influence of estrogen. Under the influence of progesterone, the mucus becomes thick, cloudy, and adherent. The woman typically assesses the secretions at her introitus with her fingers or with a piece of toilet paper before urinating each morning. Intercourse is forbidden from the time the first day that secretions are detected until the fourth day after the day of peak cervical secretions. Because vaginal lubricant or ejaculate can mask subtle changes in cervical mucus, sexual arousal and intercourse are restricted to alternate days to permit accurate assessment of secretions. Similarly, vaginal infections (eg, candidiasis, bacterial vaginosis) and their topical therapies can confuse the assessment, so intercourse should be delayed until these conditions have resolved. A variation of the ovulation method is the TwoDay Method, which has the woman refrain from intercourse if she has secretions either “today” or “yesterday.”2

Ovulation can be detected by measuring basal body temperature (BBT) with a digital thermometer or expanded-scale mercury thermometer at the same time each morning before arising. Just prior to ovulation, many women note a temporary dip in baseline temperature followed by a rise of at least 0.4°F, which is sustained until the next withdrawal bleed. In some applications, intercourse is not allowed until 3 days after the temperature rise. In others, intercourse may be permitted until the initial temperature dip and resumed 3 days after the initial temperature rise. For women who do not have initial temperature dips, they should consult prior months’ patterns and abstain starting 1 week before she expects the temperature rise. About 80% of women have interpretable BBTs. Other factors, such as nocturnal arising and fever, may affect a woman’s BBT.

The most comprehensive approach today is the symptothermal method, in which women use some combination of the Billings technique, the calendar method, and BBTs to determine at-risk days. In addition, a woman can check the consistency of her cervix, which softens and opens slightly with ovulation. If any of these indications suggest impending ovulation, intercourse is delayed.

These methods help couples learn more about the reproductive cycle, but they require several months of prospective data gathering before they can be effectively implemented. Traditionally, women learned their cycles and their physical signs of impending fertility during long engagements prior to sexual debut. Today, women want to start using these approaches more quickly, so new approaches are needed. The Standard Days Method using CycleBeads has allowed more rapid adoption of the calendar or rhythm method.3 It is intended for women whose usual cycle length is 26 to 32 days and can be used very easily in a low-literacy population. CycleBeads is a string of colored beads with a black elastic band. The band is moved over the red colored bead the first day of the cycle. Each day after that, it is advanced over one of the dark beads. Intercourse is allowed on these days. However, on the eighth day of her cycle, she will advance to the first of 12 light beads indicating the days of abstinence. The following beads are each dark, representing safe days; bead 26 is darker than the others. If a woman’s period starts before the darker bead, her cycle was too short to rely on the beads. If she has not started her menses by the last dark bead, her cycle is too long.

Although these warnings may be too late to protect her from pregnancy during this cycle, if they happen more than once in a year, she will know that this method is probably not appropriate for her. Additional information about the Standard Days Method and CycleBeads is available from the Georgetown University Institute for Reproductive Health at http://www.irh.org/.


 
CycleBeads allows women a more rapid adoption of the calendar or rhythm method.  

In many European countries and Canada, handheld fertility detection monitors for periodic abstinence have been available for years. This method applies modern computer technology to identify safe days. The most sophisticated of these is Persona, which has a typical failure rate of about 12% and a method failure rate of about 6%.4 A woman pushes a button when her menses start each month. She opens the monitor daily to determine her vulnerability to pregnancy. If it is a safe day, a green light will illuminate; if it is a day of clear risk, a red light shines; if the computer is not able to determine the risk, a yellow light turns on. If the light is yellow, a woman puts a special strip of test paper into a midstream urine sample and places it into the analytic portion of the monitor. The machine scans the urine for luteinizing hormone and estrone-3-glucuronide.

Within 1 minute, the results are displayed to the patient as a red or green light. The data on the woman’s menstrual cycle length and her urine test results are analyzed by the computer to decrease the number of uncertain days requiring testing over time. This unit was tested in the United States several years ago, but it is not currently available in the United States.

It is probably prudent to advise patients of techniques that do not work as well as existing methods. For example, it has become popular to suggest ovulation detections kits to determine at-risk days. Unfortunately, these kits are better suited to identify the most fertile days and, in general, may not provide adequate warning of impending ovulation to provide safety during the end of the follicular phase. Additional concerns are that there have not been studies reporting effectiveness using these kits and they are expensive to use on an ongoing basis.

REFERENCES

  1. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology. 17th ed. New York, NY: Ardent Media Inc; 1998..
  2. Sinai I, Jennings V, Arevalo M. The TwoDay Algorithm: a new algorithm to identify the fertile time of the menstrual cycle. Contraception. 1999; 60(2):65-70.
  3. Arevalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception. 2002;65(5):333-338.
  4. Guida M, Bramante S, Acunzo G, Pellicano M, Cirillo D, Nappi C. Diagnosis of fertility with a personal hormonal evaluation test [Italian]. Minerva Ginecol. 2003;55(2):167-173.

 

About ARHP

ARHP is a nonprofit, national medical organization that has been educating front line providers and their patients since 1963. The organization and members are dedicated to educating physicians and health care providers, and the public about important reproductive health issues including contraception, sexually transmitted diseases, menopause, abortion, sexuality, and infertility. ARHP contact information: 2401 Pennsylvania Ave, N.W., Suite 350, Washington DC 20037-1718; ph: (202) 466-3825; fax: (202) 466-3826; e-mail: arhp@arhp.org; Web: www.arhp.org.

back to top


[ Home | CME/CE | Product News | Author Guidelines ]
[ Editorial Board | Reprints/Permissions | Archives | Circulation | Classifieds | Our Services ]


Copyright ©2000-2009 Quadrant HealthCom Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided on femalepatient.com is for educational purposes only. Use of this Web site is subject to the medical disclaimer and privacy policy.